Angiotensin-converting enzyme genetic variants do not influence response to risperidone in autistic children

Document Type : Original Article

Authors

1 Department of Pharmacology & Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Department of Psychiatry, School of Medicine, Hafez Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

3 Department of Psychiatry, UCLA-Kern, Bakersfield, California, USA.

4 Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

5 Department of Clinical Pharmacy, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

6 Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Genetics has been found to have a prominent role in autism and therefore pharmacogenetics may guide us to a better management of this disorder. Given the importance of Renin-Angiotensin System (RAS) in the function of the brain and its possible association with autism, genetic variations of RAS may influence response to autism treatment. In this study, 83 autistic children were enrolled (3 to 12 years of age). Degree of autism was confirmed by the DSM-V criteria and response to treatment was measured according to Aberrant Behavior Checklist (ABC) scale at baseline, 4 and 12 weeks of risperidone therapy. Polymorphisms (ACE I/D, rs4343 and rs4291) were determined by PCR-RFLP. Our results indicate the positive role of long term therapy in autism (12 weeks vs 4 weeks). The highest response rate in ACE ID gene was in the DD genetic variant at both 4 and 12 weeks of treatment. For the ACE A2350G gene, all genetic variants did not respond well to treatment at 4 weeks, however at 12 weeks, positive response was dominant in the AG genetic variant. Highest response rate in the ACE A240T gene belonged to the AT variant at both 4 and 12 weeks of treatment. However, our results indicate no significant association between ACE gene polymorphisms and response to risperidone therapy in autistic children based on ABC scaling. In conclusion, this study does not support the hypothesis of involvement of RAS genetics in response to risperidone in autistic children.
Keywords: Autism, Renin-angiotensin system, Angiotensin-converting enzyme, Genetic polymorphism, Single nucleotide polymorphism.
Please cite this article as: Negar Firouzabadi, Nima Ghazanfari, Ali Alavi Shoushtari, Dena Firouzabadi, Elham Haem. Angiotensin-converting enzyme genetic variants does not influence response to risperidone in autistic children. Trends in Pharmaceutical Sciences. 2022;8(3):165-174. doi: 10.30476/TIPS.2022.95522.1148

Keywords

References

1.    Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. Lancet. 2018 Aug 11;392(10146):508-520. doi: 10.1016/S0140-6736(18)31129-2. Epub 2018 Aug 2. PMID: 30078460; PMCID: PMC7398158.
2.    Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. MMWR Surveill Summ. 2018 Apr 27;67(6):1-23. doi: 10.15585/mmwr.ss6706a1. Erratum in: MMWR Morb Mortal Wkly Rep. 2018 May 18;67(19):564. Erratum in: MMWR Morb Mortal Wkly Rep. 2018 Nov 16;67(45):1280. PMID: 29701730; PMCID: PMC5919599.
3.    Mohammadi MR, Ahmadi N, Khaleghi A, Zarafshan H, Mostafavi SA, Kamali K, e al. Prevalence of Autism and its Comorbidities and the Relationship with Maternal Psychopathology: A National Population-Based Study. Arch Iran Med. 2019 Oct 1;22(10):546-553. PMID: 31679355.
4.    Ng M, de Montigny JG, Ofner M, Do MT. Environmental factors associated with autism spectrum disorder: a scoping review for the years 2003-2013. Health Promot Chronic Dis Prev Can. 2017 Jan;37(1):1-23. doi: 10.24095/hpcdp.37.1.01. PMID: 28102992; PMCID: PMC5480297.
5.    Woodbury-Smith M, Scherer SW. Progress in the genetics of autism spectrum disorder. Dev Med Child Neurol. 2018 May;60(5):445-451. doi: 10.1111/dmcn.13717. Epub 2018 Mar 25. PMID: 29574884.
6.    Geschwind DH. Genetics of autism spectrum disorders. Trends Cogn Sci. 2011 Sep;15(9):409-16. doi: 10.1016/j.tics.2011.07.003. Epub 2011 Aug 18. PMID: 21855394; PMCID: PMC3691066.
7.    De Rubeis S, Buxbaum JD. Recent advances in the genetics of autism spectrum disorder. Current neurology and neuroscience reports. 2015;15(6):36.
8.    Ramaswami G, Geschwind DH. Genetics of autism spectrum disorder. Handb Clin Neurol. 2018;147:321-329. doi: 10.1016/B978-0-444-63233-3.00021-X. PMID: 29325621.
9.    Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med. 1995 Jan;25(1):63-77. doi: 10.1017/s0033291700028099. PMID: 7792363.
10.    Schaaf CP, Zoghbi HY. Solving the autism puzzle a few pieces at a time. Neuron. 2011 Jun 9;70(5):806-8. doi: 10.1016/j.neuron.2011.05.025. Erratum in: Neuron. 2011 Jul 14;71(1):195. PMID: 21658575.
11.    DeVane CL, Charles JM, Abramson RK, Williams JE, Carpenter LA, Raven S, et al. Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial. Pharmacotherapy. 2019 Jun;39(6):626-635. doi: 10.1002/phar.2271. Epub 2019 May 29. PMID: 31063671; PMCID: PMC6555676.
12.    Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry. 2018 Feb;30(1):78-95. doi: 10.1080/09540261.2018.1458706. Epub 2018 Apr 25. PMID: 29693461.
13.    Maneeton N, Maneeton B, Putthisri S, Woottiluk P, Narkpongphun A, Srisurapanont M. Risperidone for children and adolescents with autism spectrum disorder: a systematic review. Neuropsychiatr Dis Treat. 2018 Jul 11;14:1811-1820. doi: 10.2147/NDT.S151802. PMID: 30022830; PMCID: PMC6045903.
14.    Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD005040. doi: 10.1002/14651858.CD005040.pub2. PMID: 17253538; PMCID: PMC9022437.
15.    Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord. 2013 Aug;43(8):1773-83. doi: 10.1007/s10803-012-1723-5. PMID: 23212807.
16.    Dove D, Warren Z, McPheeters ML, Taylor JL, Sathe NA, Veenstra-VanderWeele J. Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics. 2012 Oct;130(4):717-26. doi: 10.1542/peds.2012-0683. 
17.    Hawcutt DB, Thompson B, Smyth RL, Pirmohamed M. Paediatric pharmacogenomics: an overview. Arch Dis Child. 2013 Mar;98(3):232-7. doi: 10.1136/archdischild-2012-302852. 
18.    Correia C, Vicente AM. Pharmacogenetics of risperidone response and induced side effects. Per Med. 2007 Aug;4(3):271-293. doi: 10.2217/17410541.4.3.271. PMID: 29788673.
19.    Nouraei H, Firouzabadi N, Mandegary A, Zomorrodian K, Bahramali E, Shayesteh MRH, et al. Glucocorticoid Receptor Genetic Variants and Response to Fluoxetine in Major Depressive Disorder. J Neuropsychiatry Clin Neurosci. 2018 Winter;30(1):45-50. doi: 10.1176/appi.neuropsych.16120322. 
20.    Firouzabadi N, Raeesi R, Zomorrodian K, Bahramali E, Yavarian I. Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients. J Pharm Pharm Sci. 2017;20:1-7. doi: 10.18433/J3W31F. 
21.    Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998 Feb;18(2):63-101. doi: 10.1016/S0893-133X(97)00112-7. PMID: 9430133.
22.    Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol. 2002 Mar 1;438(1-2):1-14. doi: 10.1016/s0014-2999(02)01283-9. PMID: 11906704..
23.    Jenkins TA, Allen AM, Chai SY, MacGregor DP, Paxinos G, Mendelsohn FA. Interactions of angiotensin II with central dopamine. Adv Exp Med Biol. 1996;396:93-103. doi: 10.1007/978-1-4899-1376-0_10. PMID: 8726689.
24.    Mendelsohn FA, Jenkins TA, Berkovic SF. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 1993 Jun 11;613(2):221-9. doi: 10.1016/0006-8993(93)90902-y. PMID: 7514480.
25.    Yang L, Zhou HH, Ye YF, Fan XW, Wang YJ, Meng Y. Association of PS1 1/2, ACE I/D, and LRP C/T polymorphisms with Alzheimer's disease in the Chinese population: a meta-analysis of case-control studies. Genet Mol Res. 2015 Feb 6;14(1):1017-24. doi: 10.4238/2015.February.6.5. 
26.    Firouzabadi N, Shafiei M, Bahramali E, Ebrahimi SA, Bakhshandeh H, Tajik N. Association of angiotensin-converting enzyme (ACE) gene polymorphism with elevated serum ACE activity and major depression in an Iranian population. Psychiatry Res. 2012 Dec 30;200(2-3):336-42. doi: 10.1016/j.psychres.2012.05.002. 
27.    Yasar S, Varma VR, Harris GC, Carlson MC. Associations of Angiotensin Converting Enzyme-1 and Angiotensin II Blood Levels and Cognitive Function. J Alzheimers Dis. 2018;63(2):655-664. doi: 10.3233/JAD-170944. PMID: 29660936; PMCID: PMC5998658.
28.    Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution, signalling and function. Clin Sci (Lond). 2001 May;100(5):481-92. PMID: 11294688.
29.    Zhu X, Bouzekri N, Southam L, Cooper RS, Adeyemo A, McKenzie CA, et al. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet. 2001 May;68(5):1139-48. doi: 10.1086/320104. Epub 2001 Mar 27. PMID: 11283791; PMCID: PMC1226095.
30.    Firouzabadi N, Ghazanfari N, Alavi Shoushtari A, Erfani N, Fathi F, Bazrafkan M, et al. Genetic Variants of Angiotensin-Converting Enzyme Are Linked to Autism: A Case-Control Study. PLoS One. 2016 Apr 15;11(4):e0153667. doi: 10.1371/journal.pone.0153667. PMID: 27082637; PMCID: PMC4833406.
31.    Vahia VN. Diagnostic and statistical manual of mental disorders 5: A quick glance. Indian J Psychiatry. 2013 Jul;55(3):220-3. doi: 10.4103/0019-5545.117131. PMID: 24082241; PMCID: PMC3777342.
32.    Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985 Mar;89(5):485-91. PMID: 3993694.
33.    Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004 Nov;114(5):e634-41. doi: 10.1542/peds.2003-0264-F. 
34.    Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi M, Hassanzadeh E, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2013 Jan;225(1):51-9. doi: 10.1007/s00213-012-2796-8. 
35.    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215. doi: 10.1093/nar/16.3.1215. 
36.    Firouzabadi N, Tajik N, Shafiei M, Ebrahimi SA, Bakhshandeh H. Interaction of A-240T and A2350G related genotypes of angiotensin-converting enzyme (ACE) is associated with decreased serum ACE activity and blood pressure in a healthy Iranian population. Eur J Pharmacol. 2011 Oct 1;668(1-2):241-7. doi: 10.1016/j.ejphar.2011.07.023. Epub 2011 Jul 28. PMID: 21810419.
37.    Firouzabadi N, Tajik N, Bahramali E, Bakhshandeh H, Maadani M, Shafiei M. Gender specificity of a genetic variant of angiotensin-converting enzyme and risk of coronary artery disease. Mol Biol Rep. 2013 Aug;40(8):4959-65. doi: 10.1007/s11033-013-2596-1. Epub 2013 May 10. PMID: 23661020.
38.    Geschwind DH, State MW. Gene hunting in autism spectrum disorder: on the path to precision medicine. Lancet Neurol. 2015 Nov;14(11):1109-20. doi: 10.1016/S1474-4422(15)00044-7. Epub 2015 Apr 16. 
39.    Depino AM. Peripheral and central inflammation in autism spectrum disorders. Mol Cell Neurosci. 2013 Mar;53:69-76. doi: 10.1016/j.mcn.2012.10.003. Epub 2012 Oct 13. PMID: 23069728.
40.    Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, Varsou A, et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol. 2005 Sep;33(3):195-201. doi: 10.1016/j.pediatrneurol.2005.03.014. 
41.    Benicky J, Sánchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology. 2011 Mar;36(4):857-70. doi: 10.1038/npp.2010.225. 
42.    Firouzabadi N, Nazariat A, Zomorrodian K. DRD3 Ser9Gly Polymorphism and Its Influence on Risperidone Response in Autistic Children. J Pharm Pharm Sci. 2017;20(1):445-452. doi: 10.18433/J3H63T. PMID: 29249220.
43.    Rahmani Z, Fayyazi Bordbar MR, Dibaj M, Alimardani M, Moghbeli M. Genetic and molecular biology of autism spectrum disorder among Middle East population: a review. Hum Genomics. 2021 Mar 12;15(1):17. doi: 10.1186/s40246-021-00319-2. 
44.    Kowiański P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. Cell Mol Neurobiol. 2018 Apr;38(3):579-593. doi: 10.1007/s10571-017-0510-4. Epub 2017 Jun 16. 
45.    Garcia KL, Yu G, Nicolini C, Michalski B, Garzon DJ, Chiu VS, et al. Altered balance of proteolytic isoforms of pro-brain-derived neurotrophic factor in autism. J Neuropathol Exp Neurol. 2012 Apr;71(4):289-97. doi: 10.1097/NEN.0b013e31824b27e4. 
46.    Saghazadeh A, Rezaei N. Brain-Derived Neurotrophic Factor Levels in Autism: A Systematic Review and Meta-Analysis. J Autism Dev Disord. 2017 Apr;47(4):1018-1029. doi: 10.1007/s10803-016-3024-x. PMID: 28138831.
47.    Szekeres M, Nádasy GL, Turu G, Süpeki K, Szidonya L, Buday L, et al. Angiotensin II-induced expression of brain-derived neurotrophic factor in human and rat adrenocortical cells. Endocrinology. 2010 Apr;151(4):1695-703. doi: 10.1210/en.2009-1060.
48.    Naert G, Maurice T, Tapia-Arancibia L, Givalois L. Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats. Psychoneuroendocrinology. 2007 Sep-Nov;32(8-10):1062-78. doi: 10.1016/j.psyneuen.2007.09.002. 
49.    Curin JM, Terzić J, Petković ZB, Zekan L, Terzić IM, Susnjara IM. Lower cortisol and higher ACTH levels in individuals with autism. J Autism Dev Disord. 2003 Aug;33(4):443-8. doi: 10.1023/a:1025019030121. PMID: 12959423.
50.    Maussion G, Moalic JM, Simonneau M, Gorwood P, Ramoz N. Increased expression of BDNF mRNA in the frontal cortex of autistic patients. Behav Brain Res. 2019 Feb 1;359:903-909. doi: 10.1016/j.bbr.2018.06.023. 
51.    Angelucci F, Mathé AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res. 2000 Jun 15;60(6):783-94. doi: 10.1002/1097-4547(20000615)60:6<783::AID-JNR11>3.0.CO;2-M. PMID: 10861791.
52.    Huang E, Hettige NC, Zai G, Tomasi J, Huang J, Zai CC, et al. BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis. Pharmacogenomics J. 2019 Jun;19(3):269-276. doi: 10.1038/s41397-018-0041-5. Epub 2018 Sep 5. PMID: 30181602.
53.    Theoharides TC, Zhang B. Neuro-inflammation, blood-brain barrier, seizures and autism. J Neuroinflammation. 2011 Nov 30;8:168. doi: 10.1186/1742-2094-8-168. 
54.    Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, et al. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem. 2000 Sep 22;275(38):29717-23. doi: 10.1074/jbc.M003128200. PMID: 10843995.
55.    Kandalam U, Clark MA. Angiotensin II activates JAK2/STAT3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes. Regul Pept. 2010 Jan 8;159(1-3):110-6. doi: 10.1016/j.regpep.2009.09.001. PMID: 19748527.
56.    Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke. 2004 Jul;35(7):1726-31. doi: 10.1161/01.STR.0000129788.26346.18. 
57.    Chen ML, Tsai TC, Wang LK, Lin YY, Tsai YM, Lee MC, et al. Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-α-directed cell apoptosis in neutrophils. Int Immunopharmacol. 2012 Jan;12(1):197-204. doi: 10.1016/j.intimp.2011.11.011. 
58.    Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology. 2006 Aug;13(3):171-81. doi: 10.1016/j.pathophys.2006.05.007. 
59.    Rodriguez-Pallares J, Rey P, Parga JA, Muñoz A, Guerra MJ, Labandeira-Garcia JL. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis. 2008 Jul;31(1):58-73. doi: 10.1016/j.nbd.2008.03.003. E
60.    Al-Amin MM, Choudhury MFR, Chowdhury AS, Chowdhury TR, Jain P, Kazi M, et al. Pretreatment With Risperidone Ameliorates Systemic LPS-Induced Oxidative Stress in the Cortex and Hippocampus. Front Neurosci. 2018 Jun 8;12:384. doi: 10.3389/fnins.2018.00384.
61.    Zerin Khan F, Sultana SP, Akhter N, Mosaddek ASM. Effect of Olanzapine and Risperidone on Oxidative Stress in Schizophrenia Patients. Int Biol Biomed J. 2018;4(2):89-97.
Trends in Pharmaceutical Sciences
Volume 8, Issue 3
September 2022
Pages 165-174

Files

Share

How to cite

Statistics